Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rhonda Gentry

Hematology & Oncology Little Rock, AR Medical Doctor

NPI 1891834016 CMS profile 40468

8901 Carti Way, Little Rock, AR 72205

Open in the dashboard

General payments

$3,644

17 records reported · program years 2019–2025

Research payments

$6,597

Paid to them · 55 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$323,955 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Rhonda Gentry of Little Rock, AR is reported in the CMS Open Payments database as having received $3,644 across 17 general payments and $6,597 in research payments paid to them. Separately, studies naming them as principal investigator received $323,955 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 71st percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $20 1
2023 General $144 3
2023 Research $843 10
2022 Research $2,000 17
2021 General $120 3
2021 Research $2,507 18
2020 General $3,100 2
2020 Research $1,248 10
2019 General $259 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rhonda Gentry
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Rhonda Gentry were reported at $20. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Rhonda Gentry Hematology & Oncology median Middle half National median
2019 $259 $529 $121–$2,516 $163
2020 $3,100 $339 $82–$2,213 $114
2021 $120 $263 $49–$1,965 $132
2022 $0 $416 $103–$2,395 $149
2023 $144 $542 $125–$2,646 $160
2024 $0 $692 $141–$3,008 $164
2025 $20 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sirtex Medical Inc $3,103 2 payments
  2. Seattle Genetics, Inc. $318 6 payments
  3. Regeneron Healthcare Solutions, Inc. $98 1 payment
  4. Pfizer Inc. $48 3 payments
  5. AstraZeneca Pharmaceuticals LP $20 1 payment
  6. Pharmacyclics LLC, An AbbVie Company $16 1 payment
  7. Janssen Pharmaceuticals, Inc $16 1 payment
  8. Gilead Sciences, Inc. $12 1 payment
  9. Foundation Medicine, Inc. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Honoraria $3,000 1 payment
  2. Food and Beverage $372 8 payments
  3. Education $272 8 payments
Products named General payments · program years 2019–2025
  1. SIR-Spheres Microspheres $3,103 2 payments
  2. ADCETRIS $126 4 payments
  3. LIBTAYO $98 1 payment
  4. IBRANCE $37 2 payments
  5. LYNPARZA $20 1 payment
  6. EPKINLY $16 1 payment
  7. IMBRUVICA $16 1 payment
  8. XARELTO $16 1 payment
  9. FOUNDATIONONE CDX $12 1 payment
  10. FOUNDATIONONE $12 1 payment
  11. Other $47 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $6,597 55 payments

Prescribing to Medicare patients

Part D · data year 2024 · 61 drugs

Part D claims

3,303

Median for Hematology-Oncology: 604

Drug cost

$4,336,257

Median for Hematology-Oncology: $1,306,514

Branded share of claims

32.6%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ibrance Palbociclib Brand 63 $969,228
Imbruvica Ibrutinib Brand 42 $610,251
Cabometyx Cabozantinib S-Malate Brand 18 $460,408
Jakafi Ruxolitinib Phosphate Brand 21 $388,081
Neulasta Onpro Pegfilgrastim Brand 56 $348,455
Keytruda Pembrolizumab Brand 30 $337,826
Verzenio Abemaciclib Brand 19 $285,122
Libtayo Cemiplimab-Rwlc Brand 15 $157,904
Somatuline Depot Lanreotide Acetate Brand 13 $122,313
Mvasi Bevacizumab-Awwb Brand 25 $110,717

The 10 drugs with the highest cost, of 61 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 169 billing codes

Paid by Medicare

$1,602,707

Of which drugs: $1,181,667

Medicare patients

906

Average age 74

Services billed

83,446

641 women, 265 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 61%
Arthritis 49%
Ischemic heart disease 39%
Diabetes 34%
Depression 30%
Chronic kidney disease 27%
Atrial fibrillation 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, nivolumab, 1 mg J9299 Office 11 8,940 $220,389
Injection, pembrolizumab, 1 mg J9271 Office 13 3,600 $161,508
Injection, denosumab, 1 mg J0897 Office 17 3,660 $75,541
Injection, ferric derisomaltose, 10 mg J1437 Office 18 1,900 $29,755
Injection, epoetin alfa, (for non-esrd use), 1000 units J0885 Office 26 2,020 $12,878
Influenza vaccine, trivalent derived from cell cultures 90661 Office 19 19 $686
Injection, palonosetron hcl, 25 mcg J2469 Office 19 700 $513
Infusion, normal saline solution , 1000 cc J7030 Office 18 58 $120
Injection, granisetron hydrochloride, 100 mcg J1626 Office 25 440 $116
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 38 1,248 $113

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

72 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record